Role of halogen bonds in thyroid hormone receptor selectivity: Pharmacophore-based 3d-qssr studies

Journal of Chemical Information and Modeling

Volumn 49, Issue 11, 2009, Pages 2606-2616

  Valadares, Napoleao F ^a   Salum, Lívia B ^a   Polikarpov, Igor ^a   Andricopulo, Adriano D ^a   Garratt, Richard C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTATIONAL CHEMISTRY; ENDOCRINOLOGY; LIGANDS; PHARMACODYNAMICS;

COMPARATIVE MOLECULAR FIELD ANALYSIS; HYPERCHOLESTEROLEMIA; MOLECULAR DETERMINANTS; PHARMACOLOGICAL EFFECTS; PHYSIOLOGICAL EFFECTS; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP (3D QSAR); THREE-DIMENSIONAL QUANTITATIVE STRUCTURES; THYROID HORMONE RECEPTOR;

HORMONES;

HALOGEN; LIGAND; THYROID HORMONE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; HALOGENS; LIGANDS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THYROID HORMONES;

EID: 72949118944     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900316e     Document Type: Article

References (50)

1. Ribeiro, R. C.; Kushner, P. J.; Baxter, J. D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 1995, 46, 443-453.
2. Yen, P. M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81, 1097-1142.
3. Hiroi, Y.; Kim, H. H.; Ying, H.; Furuya, F.; Huang, Z.; Simoncini, T.; Noma, K.; Ueki, K.; Nguyen, N. H.; Scanlan, T. S.; Moskowitz, M. A.; Cheng, S. Y.; Liao, J. K. Rapid nongenomic actions of thyroid hormone. Proc. Natl. Acad. Sci. U S A 2006, 103, 14104-14109.
4. Baxter, J. D.; Dillmann, W. H.; West, B. L.; Huber, R.; Furlow, J. D.; Fletterick, R. J.; Webb, P.; Apriletti, J. W.; Scanlan, T. S. Selective modulation of thyroid hormone receptor action. J. Steroid Biochem. Mol. Biol. 2001, 76, 31-42.
5. Grover, G. J.; Mellstrom, K.; Ye, L.; Malm, J.; Li, Y. L.; Bladh, L. G.; Sleph, P. G.; Smith, M. A.; George, R.; Vennstrom, B.; Mookhtiar, K.; Horvath, R.; Speelman, J.; Egan, D.; Baxter, J. D. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. U S A 2003, 100, 10067-10072.
6. Brenta, G.; Danzi, S.; Klein, I. Potential therapeutic applications of thyroid hormone analogs. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3, 632-640.
7. Bryzgalova, G.; Effendic, S.; Khan, A.; Rehnmark, S.; Barbounis, P.; Boulet, J.; Dong, G.; Singh, R.; Shapses, S.; Malm, J.; Webb, P.; Baxter, J. D.; Grover, G. J. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J. Steroid Biochem. Mol. Biol. 2008, 111, 262-267.
8. Erion, M. D.; Cable, E. E.; Ito, B. R.; Jiang, H.; Fujitaki, J. M.; Finn, P. D.; Zhang, B. H.; Hou, J.; Boyer, S. H.; van Poelje, P. D.; Linemeyer, D. L. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. U S A 2007, 104, 15490-15495.
9. Wikstrom, L.; Johansson, C.; Salto, C.; Barlow, C.; Campos Barros, A.; Baas, F.; Forrest, D.; Thoren, P.; Vennstrom, B. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. Embo J. 1998, 17, 455-461.
10. Ye, L.; Li, Y. L.; Mellstrom, K.; Mellin, C.; Bladh, L. G.; Koehler, K.; Garg, N.; Garcia Collazo, A. M.; Litten, C.; Husman, B.; Persson, K.; Ljunggren, J.; Grover, G.; Sleph, P. G.; George, R.; Malm, J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med. Chem. 2003, 46, 1580-1588.
11. Hangeland, J. J.; Doweyko, A. M.; Dejneka, T.; Friends, T. J.; Devasthale, P.; Mellstrom, K.; Sandberg, J.; Grynfarb, M.; Sack, J. S.; Einspahr, H.; Farnegardh, M.; Husman, B.; Ljunggren, J.; Koehler, K.; Sheppard, C.; Malm, J.; Ryono, D. E. Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett. 2004, 14, 3549-3553.
12. Hedfors, A.; Appelqvist, T.; Carlsson, B.; Bladh, L. G.; Litten, C.; Agback, P.; Grynfarb, M.; Koehler, K. F.; Malm, J. Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J. Med. Chem. 2005, 48, 3114-3117.
13. Li, Y. L.; Litten, C.; Koehler, K. F.; Mellstrom, K.; Garg, N.; Garcia Collazo, A. M.; Farnegard, M.; Grynfarb, M.; Husman, B.; Sandberg, J.; Malm, J. Thyroid receptor ligands. Part 4: 4′-amido bioisosteric ligands selective for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett. 2006, 16, 884-886. (Pubitemid 43059844)
14. Garcia Collazo, A. M.; Koehler, K. F.; Garg, N.; Farnegardh, M.; Husman, B.; Ye, L.; Ljunggren, J.; Mellstrom, K.; Sandberg, J.; Grynfarb, M.; Ahola, H.; Malm, J. Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett. 2006, 16, 1240-1244. (Pubitemid 43142998)
15. Baxter, J. D.; Webb, P.; Grover, G.; Scanlan, T. S. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol. Metab. 2004, 15, 154-157.
16. Scanlan, T. S. Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail. Rev. 2008, DOI: 10.1007/s10741-008-9122- x.
17. Borngraeber, S.; Budny, M. J.; Chiellini, G.; Cunha-Lima, S. T.; Togashi, M.; Webb, P.; Baxter, J. D.; Scanlan, T. S.; Fletterick, R. J. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. U S A 2003, 100, 15358-15363.
18. Togashi, M.; Borngraeber, S.; Sandler, B.; Fletterick, R. J.; Webb, P.; Baxter, J. D. Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design. J. Steroid Biochem. Mol. Biol. 2005, 93, 127-137.
19. Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.; Kushner, P. J.; Baxter, J. D.; Fletterick, R. J.; Yamamoto, K. R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998, 12, 3343-3356.
20. Valadares, N. F.; Polikarpov, I.; Garratt, R. C. Ligand induced interaction of thyroid hormone receptor beta with its coregulators. J. Steroid Biochem. Mol. Biol. 2008, 112, 205-212.
21. Webb, P.; Nguyen, N. H.; Chiellini, G.; Yoshihara, H. A.; Cunha Lima, S. T.; Apriletti, J. W.; Ribeiro, R. C.; Marimuthu, A.; West, B. L.; Goede, P.; Mellstrom, K.; Nilsson, S.; Kushner, P. J.; Fletterick, R. J.; Scanlan, T. S.; Baxter, J. D. Design of thyroid hormone receptor antagonists from first principles. J. Steroid Biochem. Mol. Biol. 2002, 83, 59-73. (Pubitemid 37040642)
22. Martínez, L.; Webb, P.; Polikarpov, I.; Skaf, M. S. Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands. J. Med. Chem. 2006, 49, 23-26.
23. Martinez, L.; Polikarpov, I.; Skaf, M. S. Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: Simulations using a novel multi-point steered molecular dynamics approach. J. Phys. Chem. B 2008, 112, 10741-10751.
24. Cherkasov, A.; Ban, F.; Santos-Filho, O.; Thorsteinson, N.; Fallahi, M.; Hammond, G. L. An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin. J. Med. Chem. 2008, 51, 2047-2056.
25. Chen, C. K.-M.; Hudock, M. P.; Zhang, Y.; Guo, R. T.; Cao, R.; No, J. H.; Liang, P. H.; Ko, T. P.; Chang, T. H.; Chang, S. C.; Song, Y.; Axelson, J.; Kumar, A.; Wang, A. H.; Oldfield, E. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J. Med. Chem. 2008, 51, 5594-5607.
26. Salum, L. B.; Polikarpov, I.; Andricopulo, A. D. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. J. Chem. Inf. Model. 2008, 48, 2243-2253.
27. Cramer, R. D., 3rd; Patterson, D. E.; Bunce, J. D. Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res. 1989, 291, 161-165.
28. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular-Field Analysis (Comfa) 0.1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
29. Valadares, N. F.; Castilho, M. S.; Polikarpov, I.; Garratt, R. C. 2D QSAR studies on thyroid hormone receptor ligands. Bioorg. Med. Chem. 2007, 15, 4609-4617.
30. Sandler, B.; Webb, P.; Apriletti, J. W.; Huber, B. R.; Togashi, M.; Cunha Lima, S. T.; Juric, S.; Nilsson, S.; Wagner, R.; Fletterick, R. J.; Baxter, J. D. Thyroxine-thyroid hormone receptor interactions. J. Biol. Chem. 2004, 279, 55801-55808.
31. Castilho, M. S.; Postigo, M. P.; de Paula, C. B.; Montanari, C. A.; Oliva, G.; Andricopulo, A. D. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors. Bioorg. Med. Chem. 2006, 14, 516-527.
32. Guido, R. V.; Oliva, G.; Montanari, C. A.; Andricopulo, A. D. Structural basis for selective inhibition of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase: molecular docking and 3D QSAR studies. J. Chem. Inf. Model. 2008, 48, 918-929.
33. Chen, Y.; Li, H.; Tang, W.; Zhu, C.; Jiang, Y.; Zou, J.; Yu, Q.; You, Q. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur. J. Med. Chem. 2008, 44, 2868-2876.
34. Nascimento, A. S.; Dias, S. M.; Nunes, F. M.; Aparicio, R.; Ambrosio, A. L.; Bleicher, L.; Figueira, A. C.; Santos, M. A.; de Oliveira Neto, M.; Fischer, H.; Togashi, M.; Craievich, A. F.; Garratt, R. C.; Baxter, J. D.; Webb, P.; Polikarpov, I. Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. J. Mol. Biol. 2006, 360, 586-598.
35. Koehler, K.; Gordon, S.; Brandt, P.; Carlsson, B.; Backsbro-Saeidi, A.; Apelqvist, T.; Agback, P.; Grover, G. J.; Nelson, W.; Grynfarb, M.; Farnegardh, M.; Rehnmark, S.; Malm, J. Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. J. Med. Chem. 2006, 49, 6635-6637. (Pubitemid 44749727)
36. Wagner, R. L.; Huber, B. R.; Shiau, A. K.; Kelly, A.; Cunha Lima, S. T.; Scanlan, T. S.; Apriletti, J. W.; Baxter, J. D.; West, B. L.; Fletterick, R. J. Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol. 2001, 15, 398-410.
37. Dow, R. L.; Schneider, S. R.; Paight, E. S.; Hank, R. F.; Chiang, P.; Cornelius, P.; Lee, E.; Newsome, W. P.; Swick, A. G.; Spitzer, J.; Hargrove, D. M.; Patterson, T. A.; Pandit, J.; Chrunyk, B. A.; LeMotte, P. K.; Danley, D. E.; Rosner, M. H.; Ammirati, M. J.; Simons, S. P.; Schulte, G. K.; Tate, B. F.; DaSilva-Jardine, P. Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. Bioorg. Med. Chem. Lett. 2003, 13, 379-382.
38. Du, J.; Qin, J.; Liu, H.; Yao, X. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta. J. Mol. Graph. Model. 2008, 27, 95-104.
39. Chiellini, G.; Nguyen, N. H.; Apriletti, J. W.; Baxter, J. D.; Scanlan, T. S. Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives. Bioorg. Med. Chem. 2002, 10, 333-346.
40. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonds in biological molecules. Proc Natl Acad Sci U S A 2004, 101, 16789-16794.
41. Politzer, P.; Lane, P.; Concha, M. C.; Ma, Y.; Murray, J. S. An overview of halogen bonding. J. Mol. Model. 2007, 13, 305-311.
42. Voth, A. R.; Hays, F. A.; Ho, P. S. Directing macromolecular conformation through halogen bonds. Proc Natl Acad Sci U S A 2007, 104, 6188-6193.
43. Metrangolo, P.; Resnati, G. Halogen versus hydrogen. Science 2008, 321, 918-919.
44. Lu, Y.; Shi, T.; Wang, Y.; Yang, H.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. Halogen bondingsA novel interaction for rational drug design. J. Med. Chem. 2009, 52, 2854-2862.
45. Richmond, N. J.; Abrams, C. A.; Wolohan, P. R.; Abrahamian, E.; Willett, P.; Clark, R. D. GALAHAD: 1. pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput.-Aided Mol. Des 2006, 20, 567-587.
46. Shepphird, J. K.; Clark, R. D. A marriage made in torsional space: Using GALAHAD models to drive pharmacophore multiplet searches. J. Comput.-Aided Mol. Des. 2006, 20, 763-771.
47. Clark, R. D.; Abrahamian, E. Using a staged multi-objective optimization approach to find selective pharmacophore models. J. Comput. Aided Mol. Des. 2008, DOI: 10.1007/s10822-008-9227-2.
48. Sutherland, J. J.; O'Brien, L. A.; Weaver, D. F. A comparison of methods for modeling quantitative structure-activity relationships. J. Med. Chem. 2004, 47, 5541-5554.
49. Tintori, C.; Corradi, V.; Magnani, M.; Manetti, F.; Botta, M. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J. Chem. Inf. Model. 2008, 48, 2166-2179.
50. Salum, L. B.; Polikarpov, I.; Andricopulo, A. D. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies. J. Mol. Graph. Model. 2007, 26, 434-442